ACM
SYRE icon

ADAR1 Capital Management’s Spyre Therapeutics SYRE Stock Holding History

ADAR1 Capital Management’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.2M Sell
283,982
-54,341
-16% -$3.97M 1.15% 15
2026
Q1 		$17.1M Buy
338,323
+304,272
+894% +$11.5M 1% 20
2025
Q4 		$1.12M Hold
34,051
– – 0.08% 125
2025
Q3 		$571K Hold
34,051
– – 0.05% 127
2025
Q2 		$510K Buy
34,051
+19,018
+127% +$281K 0.08% 117
2025
Q1 		$243K Buy
+15,033
New +$313K 0.05% 139
2024
Q4 		– Sell
-12,560
Closed -$369K – 294
2024
Q3 		$369K Sell
12,560
-22,620
-64% -$630K 0.06% 132
2024
Q2 		$827K Sell
35,180
-14,320
-29% -$483K 0.16% 74
2024
Q1 		$1.88M Buy
49,500
+43,060
+669% +$1.25M 0.43% 47
2023
Q4 		$139K Buy
+6,440
New +$88.7K 0.05% 90

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

ADAR1 Capital Management's SYRE Position: Q2 2026 in Review

ADAR1 Capital Management reduced its Spyre Therapeutics (SYRE) stake by 16% in Q2 2026, selling an estimated $3.97M and leaving 283,982 shares worth $25.2M. The position accounts for 1.15% of the portfolio, ranked #15.

ADAR1 Capital Management first reported a position in SYRE in Q4 2023 and has held it in 10 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • ADAR1 Capital Management held 283,982 shares of Spyre Therapeutics worth $25.2M as of Q2 2026.
  • ADAR1 Capital Management sold 54,341 Spyre Therapeutics shares in Q2 2026, an estimated $3.97M.
  • Spyre Therapeutics made up 1.15% of ADAR1 Capital Management's portfolio in Q2 2026, its #15 holding.
  • ADAR1 Capital Management first reported a position in Spyre Therapeutics in Q4 2023 and has held it in 10 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.